Testing effectiveness (Phase 2)Study completedNCT02255097
What this trial is testing
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Who this might be right for
Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 172